Compassion is an essential component of the moral compass that informs our behavior as physicians. It is at the basis of the principle that the needs of the patient are paramount. However, there are instances in which ethical, legal, or logistical considerations may constrain physicians from acting with what they interpret as compassion. This article explores one such dilemma that sooner or later is apt to confront the clinician.
Most available drugs have been approved by phase 3 trials for some specific indication or indications. Because the risks and benefits have been identified through appropriate testing in human subjects, there is no hesitancy to use them for the appropriate indications. However, there are instances in which we find ourselves tempted to use an “approved” drug for another indication for which the risks and benefits have not been established by phase 3 trials. In addition, we may contemplate the use of drugs that are in the process of being evaluated or for which such evaluations are contemplated. We occasionally must decide whether we should enroll a patient in a clinical trial in which he or she may receive a placebo or a drug that is by definition yet to be approved. In making all of these decisions, it is important to recognize that the likely alternative—not to treat the patient with the drug in question—carries with it risks that may be more difficult to anticipate than those established in the phase 3 trial of the drug. Either course of action may also leave the physician vulnerable to allegations of medical negligence.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.